{"nctId":"NCT02282293","briefTitle":"Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)","startDateStruct":{"date":"2014-12-09","type":"ACTUAL"},"conditions":["Malaria","Human Immunodeficiency Virus"],"count":200,"armGroups":[{"label":"Daily TS + Monthly DP pregnancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)"]},{"label":"Daily TS + DP Placebo pregnancy","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)"]}],"interventions":[{"name":"Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)","otherNames":["Duo-Cotexin (Holley-Cotec)"]},{"name":"Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Intrauterine pregnancy confirmed by ultrasound\n2. Estimated gestational age between 12-28 weeks\n3. Confirmed to be HIV-infected by Uganda country standard rapid HIV test\n4. 16 years of age or older\n5. Residency within 30 km of the study clinic\n6. Provision of informed consent\n7. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol\n8. Plan to deliver in the hospital\n\nExclusion Criteria:\n\n1. History of serious adverse event to TS or DP\n2. Refusal to take cART during pregnancy or as part of routine HIV care\n3. Active medical problem requiring inpatient evaluation at the time of screening\n4. Intention of moving more than 30 km from the study clinic\n5. Active WHO stage 4 condition not stable under treatment\n6. Signs or symptoms of early or active labor\n7. Currently on ritonavir\n8. Currently taking drugs associated with known risk of Torsades de pointes\n9. Currently taking CYP3A inhibitor medications which potentially inhibit the metabolism of piperaquine\n10. History of cardiac problems or fainting","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Placental Malaria","description":"The primary outcome will be the prevalence of placental malaria based on placental histopathology and dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence of placental infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Malaria, Pregnant Women","description":"The primary outcome will be the incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Parasitemia at Delivery by Microscopy and LAMP","description":"Proportion of women with parasitemia detected by microscopy or LAMP at delivery","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)","description":"Proportion of placental blood samples positive for malaria by microscopy or PCR","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Monthly Routine Visits With Positive Blood Samples for Parasites","description":"Proportion of monthly routine blood samples positive by LAMP for parasites","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)","description":"Proportion with low birth weight (\\<2500 gm), spontaneous abortion (\\<28 weeks), stillbirth (fetal demise ≥28 weeks), congenital anomaly, or preterm delivery (\\<37 weeks)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia","description":"Anemia (hemoglobin less than 11g/dL) measured every 8 weeks during pregnancy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":100},"commonTop":["Abdominal pain","Cough","Anemia","Headache","Malaise"]}}}